RIGL RIGEL PHARMACEUTICALS INC

Nasdaq Pharmaceutical Preparations DE CIK: 0001034842
AI RATING
HOLD
65% Confidence

Investment Thesis

Strong revenue growth of 64% is undermined by flat net income and severely weak free cash flow conversion ($2.3M FCF on $58.8M revenue), indicating structural profitability challenges. The 2.2% ROE and 1.7% ROA reveal poor capital efficiency, suggesting revenue growth is not translating into shareholder value creation.

Strengths

  • + Robust revenue growth of 64.1% year-over-year demonstrates market traction
  • + Healthy operating margin (20.2%) and net margin (14.7%) provide profitability foundation
  • + Strong liquidity with current ratio 2.62x and conservative balance sheet with Debt/Equity of 0.11x

Risks

  • ! Net income stagnation (0% growth) despite strong revenue growth signals margin compression or rising operating costs
  • ! Critical cash conversion gap: $8.7M net income but only $2.7M operating cash flow suggests earnings quality concerns
  • ! Abysmal return metrics (2.2% ROE, 1.7% ROA) indicate capital is deployed inefficiently with minimal value generation

Key Metrics to Watch

Financial Metrics

Revenue
58.8M
Net Income
8.7M
EPS (Diluted)
$0.44
Free Cash Flow
2.3M
Total Assets
504.6M
Cash
24.4M

Profitability Ratios

Gross Margin 29.6%
Operating Margin 20.2%
Net Margin 14.7%
ROE 2.2%
ROA 1.7%
FCF Margin 3.9%

Balance Sheet & Liquidity

Current Ratio
2.62x
Quick Ratio
2.48x
Debt/Equity
0.11x
Debt/Assets
20.8%
Interest Coverage
8.49x
Long-term Debt
45.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-08T08:38:03.632837 | Data as of: 2026-03-31 | Powered by Claude AI